About Us

Procaps Group, S.A. ("Procaps Group") (NASDAQ: PROC) is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over the counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

ESG Report 2022

Our Sustainable Way: Driving Innovation, shaping a Healthier Future

View Report
ESG Report

Press Realease
December 21, 2023 

Statement from the Board of Directors of Procaps Group

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Dec. 21, 2023-- Procaps Group (NASDAQ: PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders.

Read more 

Pharmaceutical Group
dedicated to delivering
health and nutrition

We employ over 5,500 people across 13 countries
 

Our products reach 
50+ markets